# VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease

> **NCT06874621** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Voyager Therapeutics** · enrollment: 52 (estimated)

## Conditions studied

- Alzheimer's Disease (AD)

## Interventions

- **DRUG:** VY7523
- **DRUG:** Placebo Comparator

## Key facts

- **NCT ID:** NCT06874621
- **Lead sponsor:** Voyager Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-03-03
- **Primary completion:** 2027-05
- **Final completion:** 2027-05
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2025-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06874621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06874621, "VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT06874621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*